A seven-year case study of a prenatal 19p13.3–p13.2 duplication found persistent developmental and growth problems alongside ...
Opus Genetics said Wednesday that the US Food and Drug Administration cleared its investigational new drug application for OPGx-RDH12, a gene therapy candidate for a rare inherited disease ...
FDA clearance enables clinical development of OPGx-RDH12 for RDH12-associated Leber congenital amaurosis, a rare inherited retinal disease that ...
Baylor Genetics, a leading diagnostic genomics partner offering a full spectrum of comprehensive genetic tests and diagnostic ...
Chromosomal abnormalities in eggs increase with age. This is a point often stated as a near-given in fertility treatment ...
A seven-year study of 7,530 Chinese patients undergoing reproductive genetic counseling found that benign chromosomal ...
FDA expands the approved use of phentolamine ophthalmic solution 0.75% to include age-related near vision impairment, which affects millions of adults in the United States. Approv ...
Detailed price information for Opus Genetics Inc (IRD-Q) from The Globe and Mail including charting and trades.
Opus Genetics , a, North Carolina-based clinical-stage biopharmaceutical company developing gene therapies for inherited ...
Single deletions may be asymptomatic, but 'multiple deletions lead to infertility'—Mouse study with comprehensive deletion of ...
OPGx-BEST1 showed improved retinal sensitivity in 75% of evaluable participants in the initial low-dose Cohort 1 of the Company’s Phase 1/2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results